The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Yeah didn't mean to sound negative, I meant there is very little to go on besides the 360p target and beyond that really is anyone's guess. I know everyone's excited but for newbies joining it feels a bit rampy to be throwing out 2000% predictions!
I agree that those saying things like 'I think £1b is too low, I'm waiting for £10-£15b' are a bit ridiculous as we simply aren't in a position to value this company. All we do know is that the figure is many multiples from where we are now.
You make some good points but I don't particularly agree with your outlook. Short term yes, but I really don't think covid is going to lead to the sort of drastic changes you're describing. They'll be a definite shift towards working more from home, yes. But I don't see a general fear of public transport ever taking shape - even now right smack bang in the middle of the pandemic people are travelling by coach and bus. The numbers will return.
Over the next decade climate change is going to be more and more of a focus. Far from a move away from public transport to individual car ownership I'm expecting the opposite. You only have to look at cities across the country and the reduce car lanes for bike lanes to show in which direction the UK for instance is going.
I know you mentioned IAG as an extreme example but it really is incomparable. Airlines have an awful lot going against them at the moment and they simply can't withstand grounded planes for any length of time. IAG is down about 68% since January, NEX is down over 70%. One is in serious trouble and the other frankly isn't.
Let's be honest any stock that is down 70% in six months is going to be up against it but I really think there is no better risk/reward profile in the entire ftse350.
Those aren't good examples. Those businesses became unviable over time whereas this is a pandemic that has made virtually every business unviable bar online retailers. There is nothing to suggest that any major shifts in the operating environment post covid will be detrimental to NEX, if anything there are reasons to believe they'll be better placed than ever to thrive in a post-covid world.
Paddy, the sp is down 200% eh? That made me chuckle.
It's pretty obvious that actions like the local lockdowns are merely enacted to keep people on their toes and for the government to appear to be taking the pandemic seriously. I agree to a degree with paddy but at the same time it's about finding a balance. Wear masks where possible, avoid unnecessary physical contact, shield the most vulnerable.
I think we might see new lows temporarily if talk of a second lockdown gets louder but as long as we don't actually go into lockdown (i'm pretty certain we won't) the share price will quickly recover on good news.
The big question is will there be anything in the update to shift the ridiculously low P/E ratio? Or will another two months of growth be enough to shift the P/E ratio?
Profits this year are expected to be somewhere around the £120m mark...so that makes the estimated P/E to be just under 2 in a company with zero debt.
Blown out of proportion? Yes. Concerning? Definitely.
The problem isn't right now, it's a few months time. The aim has to be to keep community transmission as low as possible before we enter winter proper, let's say six weeks from now. The case numbers are not so bad but it's the acceleration that's a little troubling.
It's pretty obvious that this opportunity is quite unlike anything synairgen would ever have imagined. I agree with you, the market for covid is incomparable to COPD and the situation we are all living in makes the potential astronomical - hence finncap's broker forecast essentially saying 'we can't price it'. You only have to look at the US's attempt to procure the entire global remdesivir supplies to highlight this.
I've been pondering the upcoming figures and wondering what it would take to see a genuine rerate to the share price. The last update included the news that in the US we had signed a major distribution agreement with a new global strategic partner. That alone makes me expect growth to continue month on month. So here's my (conservative)prediction:
July sales - £27m
August sales - £30m
This would take ytd sales to £120m, EBITDA to ~£80m and cash ~ £45m.
Imo this alone would see no more than a rise to £4 so we need either a bigger jump in revenues or some additional news which takes the market by surprise.
Come on Dunk, it's pretty obvious why they did that. The company is simply far too small to be taking on both the COPD market and covid at the same time and whilst the COPD market is massive and will be lucrative in the future, time is not of the essence. With the US IIs moving in there really was no choice but to put COPD on hold.
Any share that could potentially ten bag also has risks, otherwise everyone would be invested right now waiting for their fortunes. This will probably slowly trickle down until there is good news but you've got to be in it to win it if you want the big gains.
That was meant to say September, sorry.
They crossed on the 8th August so were probably paying anywhere between 58 and 60 for their shares - if they're happy buying at 60 then so am I.